Evidence map›Paper›PMID 36519153›Full record

ArticleBrain communications2022

Intellectual enrichment and genetic modifiers of cognition and brain volume in Huntington's disease.

Marina Papoutsi, Michael Flower, Davina J Hensman Moss, Peter Holmans, Carlos Estevez-Fraga, Eileanoir B Johnson, Rachael I Scahill, Geraint Rees, Douglas Langbehn, Sarah J Tabrizi and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Mild cognitive impairment in Huntington's disease: challenges and outlooks.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Marina PapoutsiUCL Huntington's Disease Centre, Queen Square Institute of Neurology, University College London, London, UK.ORCID https://orcid.org/0000-0003-0971-8361
Michael FlowerUCL Huntington's Disease Centre, Queen Square Institute of Neurology, University College London, London, UK.ORCID https://orcid.org/0000-0001-5568-6239
Davina J Hensman MossUCL Huntington's Disease Centre, Queen Square Institute of Neurology, University College London, London, UK.
Peter HolmansMRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.
Carlos Estevez-FragaUCL Huntington's Disease Centre, Queen Square Institute of Neurology, University College London, London, UK.
Eileanoir B JohnsonUCL Huntington's Disease Centre, Queen Square Institute of Neurology, University College London, London, UK.
Rachael I ScahillUCL Huntington's Disease Centre, Queen Square Institute of Neurology, University College London, London, UK.
Geraint ReesWellcome Centre for Human Neuroimaging, Queen Square Institute of Neurology, University College London, London, UK.ORCID https://orcid.org/0000-0002-9623-7007
Douglas LangbehnCarver College of Medicine, University of Iowa, Iowa City, IA, USA.
Sarah J TabriziUCL Huntington's Disease Centre, Queen Square Institute of Neurology, University College London, London, UK.
Track-HD Investigators
National Hospital for Neurology and Neurosurgery · GBCardiff University · GBIxico (United Kingdom) · GBUK Dementia Research Institute · GBUniversity of Iowa · USWellcome Centre for Human Neuroimaging · GB

Funding

Medical Research Council MR/L012936/1Medical Research Council MR/M008592/1Wellcome Trust 200181/Z/15/Z
6 · The paper itself

Abstract

An important step towards the development of treatments for cognitive impairment in ageing and neurodegenerative diseases is to identify genetic and environmental modifiers of cognitive function and understand the mechanism by which they exert an effect. In Huntington's disease, the most common autosomal dominant dementia, a small number of studies have identified intellectual enrichment, i.e. a cognitively stimulating lifestyle and genetic polymorphisms as potential modifiers of cognitive function. The aim of our study was to further investigate the relationship and interaction between genetic factors and intellectual enrichment on cognitive function and brain atrophy in Huntington's disease. For this purpose, we analysed data from Track-HD, a multi-centre longitudinal study in Huntington's disease gene carriers and focused on the role of intellectual enrichment (estimated at baseline) and the genes

Indexed as

brain-derived neurotrophic factorcognitive modifiersHuntington’s diseaseintellectual enrichmentMSH3

Identifiers

PMID36519153
PMCPMC9732861
OpenAlexW4307890708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.